MET and cancer: We based this choice on several studies demonstrating that, unlike antibodies directed to the extracellular or transmembrane domain, the use of antibodies directed to the intracellular c-Met domain correlated with poor patient outcome and their use permitted the identification of nuclear c-Met in more aggressive forms of cancer [52,53].